GEN1056 / BioNTech, Genmab - LARVOL DELTA

Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: Genmab | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Oncology • Solid Tumor

Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Genmab | Trial completion date: May 2024 ➔ Dec 2025 | Trial primary completion date: May 2024 ➔ Dec 2025

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Genmab | Trial primary completion date: Feb 2024 ➔ May 2024

Metastases • Trial primary completion date • Oncology • Solid Tumor

Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: Genmab | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Solid Tumor

Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Genmab | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Genmab

New P1 trial • Oncology • Solid Tumor